Current Report Filing (8-k)
December 07 2021 - 4:52PM
Edgar (US Regulatory)
0001721484
false
Suite 520
0001721484
2021-12-06
2021-12-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of
Earliest Event Reported): December 6, 2021
Commission File No. 001-40060
Longeveron Inc.
(Exact name of small business issuer as specified
in its charter)
Delaware
|
|
47-2174146
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
|
1951 NW 7th Avenue,
Suite 520
Miami, Florida
|
|
33136
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(305) 909-0840
|
(Issuer’s telephone number, including area code)
|
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Class A Common Stock, par value $.001 per share
|
|
LGVN
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01.
|
Regulation FD.
|
On December 6, 2021, Longeveron Inc. (the “Company”)
announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Lomecel-B for the treatment of
Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants.
ODD is intended to assist and encourage companies
to develop safe and effective therapies for the treatment of rare diseases or conditions. ODD positions Longeveron to be able to potentially
leverage a range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of FDA user
fees for the potential submission of a marketing application, and certain tax credits. Receiving ODD may also result in the product receiving
seven years market exclusivity upon approval for use in the rare disease or condition for which the product was designated if all of the
statutory and regulatory requirements are met.
The information provided under this Form 8-K (including
Exhibits 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
December 7, 2021
|
|
|
Longeveron Inc.
|
|
|
|
By:
|
/s/ Geoff Green
|
|
|
Geoff Green
|
|
|
Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
Exhibit Index
3
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Apr 2023 to Apr 2024